Comparative study between the interaction of dephosphorylated amifostine (WR-1065) and amoxicilline with pBR322 in absence and presence of cisplatin by AFM

International Journal of Pharmaceutics

Volumn 270, Issue 1-2, 2004, Pages 75-82

  Amat, E ^a   Prieto, M J ^a   Moreno, V ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Amifostine; Amoxicilline; Cisplatin AFM study; Cisplatin chemoprotection; Cisplatin toxicity

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; AMOXICILLIN; CISPLATIN; PLASMID DNA;

ARTICLE; ATOMIC FORCE MICROSCOPY; COMPARATIVE STUDY; DEPHOSPHORYLATION; DRUG DNA INTERACTION; DRUG EFFECT; DRUG TRANSFORMATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 0347022245     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.10.035     Document Type: Article

References (39)

1. Bergstrom P., Johnsson A., Bergenheim T., Henriksson R. Effects of amifostine on cisplatin-induced DNA adduct formation and toxicity in malignant glioma and normal-tissues in rat. J. Neuro-Oncol. 42:1999;13-21.
2. Bonner H.S., Shaw L.M. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid-chromatography. J. Chromatogr. 739:2000;357-362.
3. Broch H., Hamza A., Vasilescu D. Quantum molecular simulation of the radioprotection by the aminothiol WR-1065, active metabolite of amifostine (WR-2721). Part 2. Modeling of the hydrogen abstraction by C4′ of DNA deoxyribosa radical. J. Mol. Struct. Theochem. 538:2001;117-132.
4. Calabro-Jones P.M., Agulera J.A., Ward J.F., Fahey R.C. Uptake of WR2721 derivatives by cells in culture: identification of the transported from of the drug. Cancer Res. 48:1988;3634-3640.
5. Castiglione F., Dallamola A., Porcile G. Protection of normal-tissues from radiation and cytotoxic therapy. Dev. Amifostine. Tumori. 85:1999;85-91.
6. Cervantes G., Moreno V., Prieto M.J. Antitumour activity of a Pt(III) derivative of 2-mercaptopyrimidine. Metal-Based Drugs. 4:1997;9-18.
7. Cervantes G., Moreno V., Molins E., Quirós M. Pd(II) and Pt(II) D-penicillamine complexes. Crystal structure of a tridentate D-penicillamine cluster of Pd(II). Polyhedron. 17:1998;3343-3350.
8. Cervantes G., Marchal S., Prieto M.J., Pérez J.M., González V.M., Alonso C., Moreno V. DNA interaction and antitumor activity of a Pt(III) derivative of 2-mercaptopyridine. J. Inorg. Biochem. 77:1999;197-203.
9. Glover D., Glick J.H., Weiler C., Fox K., Turrisi A., Kligerman M.M. Phase I/II trials of WR-2721 and cisplatinum. Int. J. Radiat. Oncol. Bio. Phys. 12:1986;1509-1512.
10. Glover D., Glick J.H., Weiler C., Fox K., Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol. 5:1987;574-578.
11. Glover D., Grabelsky S., Fox K., Weiler C., Cannon L., Glick J. Clinical trials of WR-2721 and cis-platinum. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1201-1204.
12. Grochowski T., Samochocka K. Structural characterization of the platinum(II)-penicillin complexes. Polyhedron. 10:1991;1473-1477.
13. Hartmann J.T., Fels L.M., Knop S., Stolte H., Kanz L., Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Investigat. New Drugs. 18:2000a;281-289.
14. Hartmann J.T., Knop S., Fels L.M., Vanvangerow A., Stolte H., Kanz L., Bokemeyer C. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anti-Cancer Drugs. 11:2000b;1-6.
15. Hospers G.A.P., Eisenhauer E.A., Devries E.G.E. The sulphydryl- containing compounds WR-2721 and glutathione as radioprotective and chemoprotective agents. A review, indications for use and prospects. British J. Cancer. 80:1999;629-638.
16. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:1999;2467-2498.
17. Johnsson A., Wennerberg J. Amifostine as a protector against cisplatin-induced toxicity in nude-mice. Acta Oncol. 38:1999;247-253.
18. Jordan S.W., Yuhas J.M., Glick J. Modulation of cisplatinum renal toxicity by the radio protective agent WR-2721. Exp. Mol. Pathol. 36:1982;297-305.
19. Korst A.E.C., Eeltink C.M., Vermorken J.B., van der Vijgh W.J.F. Pharmacokinetics of amifostine and its metabolites in patients. Eur. J. Cancer. 33:1997;1425-1429.
20. Korst A.E.C., van der Sterre M.L.T., Gall H.E., Fichtinger-Schepman A.M.J., Vermorken J.B., van der Vijgh W.J.F. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin. Cancer Res. 4:1998;331-336.
21. Lippert, B. (Ed.), 1999. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, VHCA-Wiley-VCH, New York.
22. Moldoon L.L., Pagel M.A., Kroll R.A., Brummett R.E., Doolittle N.D., Zuhowski E.G., Egorin M.J., Neuwelt E.A. Delayed administration of sodium thiosulfate in animal-models reduces platinum oxotoxicity without reduction of antitumor-activity. Clin. Cancer Res. 6:2000;309-315.
23. Onoa G.B., Cervantes G., Moreno V., Prieto M.J. Study on the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy. Nucl. Acids Res. 26:1998;1473-1480.
24. Onoa G.B., Moreno V. Study of the modifications caused by cisplatin, transplatin, and Pd(II) and Pt(II) mepirizole derivatives on pBR322 DNA by atomic force microscopy. Int. J. Pharm. 245:2002;55-65.
25. Pérez-Benito J., Arias C., Amat E. A kinetic study of the reactions of cisplatin with biological thiols. N. J. Chem. 19:1995;1089-1094.
26. Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev. 99:1999;2499-2510.
27. Renner S., Klingebiel T., Niethammer D., Bruchelt G., Meissner T., Eisenbeiss F. Isotachophoretic determination of phosphate splitting from amifostine and P-nitrophenyl phosphate in serum and neuroblastoma-cells. J. Chromatography. 838:1999;251-257.
28. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature. 222:1969;385-386.
29. Samochocka K., Kruszewski M., Szumiel I. Interaction of some organic platinum(II) complexes with L5178Y-R and L5178Y-S cells. Chemico-Biol. Interact. 105:1997;145-155.
30. Santini V., Giles F.J. The potential of amifostine. from cytoprotectant to therapeutic agent. Haematologica. 84:1999;1035-1042.
31. Shaw L.M., Glover D., Turrisi A., Brown D.Q., Bonner H.S., Norfleet A.L., Weiler C., van der Vijgh W.J.F., Peters G.J. WR2721 Pharmacokinetics. Pharmacol. Ther. 39:1988;195-201.
32. Smoorenburg G.F., Degroot J.C.M.J., Hamers F.P.T., Klis S.F.L. Protection and spontaneous-recovery from cisplatin-induced hearing-loss. An. N.Y. Acad. Sci. 884:1999;192-210.
33. Souid A.K., Fahey R.C., Dubowy R.L., Newton G.L., Bernstein M.L. WR-2721 (amifostine) infusion in patients with ewings-sarcoma receiving iphosphamide and cyclophosphamide with mesna-drug and thiol levels in plasma and blood-cells a pediatric-oncology-group study. Cancer Chemother. Pharmacol. 44:1999;498-504.
34. Treskes M., Boven E., Holwerda U., Pinedo H.M., Van der Vijgh W.J.F. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res. 52:1992;2257-2260.
35. Treskes M., Nitjmans L.G., Fichtinger-Schepman A.M., van der Vijgh W.J.F. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbamate. Biochem. Pharmacol. 43:1992;1013-1019.
36. Van der Vijgh W.J.F., Peters G.J. Protection of normal-tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol). Preclin. Aspects. Semin Oncol. 21:1994;2-7.
37. Van der Vijgh W.J.F., Korst A.E.C. Amifostine (ethyol). Pharmacokinetic and pharmacodynamic effects in vivo. Eur. J. Cancer. 32A:1996;S26-S30.
38. Yuhas J.M., Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat. Rep. 64:1980;57-64.
39. Yuhas J.M., Spellman J.M., Jordan S.W., Pardini M.C., Afzal S.M.J., Culo F. Treatment of tumours with the combination of WR-2721 and cis- dichlorodiammineplatinum(II) or cyclophosphamide. Br. J. Cancer. 42:1980;574-585.